Multivariant Surface Quasispecies in a Hepatitis B Virus Chronically Infected Individual with Concomitant and Continually Positive Surface Antigen and Anti-Hbs Biomarkers - European Medical Journal


Multivariant Surface Quasispecies in a Hepatitis B Virus Chronically Infected Individual with Concomitant and Continually Positive Surface Antigen and Anti-Hbs Biomarkers

1 Mins
EMJ Hepatology [Supplement 2] ILC Congress Review 2020
*Suzane K. Ono,1 Johanna C. Craig,2 Leda Bassit,3 Rodrigo M. Abreu,1 Dimitri Gonzalez,4 Flair J. Carrilho,1 Raymond F. Schinazi3

The authors have declared no conflicts of interest.


This research was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico ([CNPq] number: 201812/2014-2 to RMA, 308609/2018-2, and 551407/2007-7 to SKO), SPRINT Emory-FAPESP (2017/50042-2), and in part by the National Institutes of Health (NIH) sponsored Center for AIDS Research Grant P30AI050409 and 1R01AI132833 (to RFS).

EMJ Hepatol. ;8[Suppl 2]:37-39. Abstract Review No: AR5.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list


Coexistence of hepatitis B virus (HBV) surface antigen (HBsAg) and antibodies (anti-HBs) can be found in 2.3–5.2% of chronic HBV (CHB) infected individuals. Recent reports have indicated that the presence of both biomarkers is associated with a high risk of hepatocellular carcinoma.1,2 However, previous studies with clinical samples presenting both biomarkers have demonstrated that the presence of variants in the HBsAg surface (S) gene and anti-HBs subtype can non-specifically contribute to the coexistence of these two biomarkers in CHB.3


In this study, HBsAg variants were analysed in a clinical sample from a 43-year-old female with CHB, with prolonged (>7 years) coexistence of HBsAg and anti-HBs, HBV e-antigen-negative, and treatment with tenofovir disoproxil fumarate. Total DNA was purified from plasma and HBV DNA was amplified. Next-generation sequencing and a novel HBV-specific assembly/machine-learning tool for quasispecies were applied for the analysis of the S gene (GATACA Assembly Tool [GAT], Newport, Virginia, USA).


The authors determined the frequency of 17 site variants in the S gene (Table 1). Variants Y100S and L127P occurred together in the same haplotypes and eight of the sites studied presented with a variant with a stop codon. Additionally, several quasispecies of the same amino acid variation in the variants’ pool were found within this clinical sample. In addition, the study demonstrated that defective HBsAg variants can coexist with the wild type and other functional variants. Seven site variants were found in the ‘a’ determinant amino acid region of HBsAg, which could explain its persistence despite the presence of anti-HBs.

Table 1: Surface gene sites with amino acids identified with GATACA Assembly Tool (GATACA, Newport, Virginia, USA).
*Amino acid with different nucleotides.


Considering that the HBsAg S gene is a potential target for antiviral development and HBsAg seroconversion is a potential outcome for a functional cure, understanding the dynamics of these variants can help identify strategies of use for the novel direct-acting antiviral agents.

Jang JS et al. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection. J Med Virol. 2009;81(9):1531-8. Jin ZZ et al. Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load. Braz J Infect Dis. 2019;23(5):343-51. Rodriguez-Frias F et al. Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol. 2013;19(41):6995-7023.